Reusable medical device testing

What Is Reusable Medical Device Testing and Why Does It Matter?

Reusable medical device testing is the structured process of evaluating whether a device remains safe, chemically stable, and functionally effective after repeated use and reprocessing cycles. At Materials Metric, we help manufacturers, hospitals, and regulatory teams confirm that reusable devices meet strict safety benchmarks before they reach patients again.

Reprocessing introduces real risks. Each sterilization cycle, cleaning agent, and handling event can degrade materials, introduce contaminants, or alter surface chemistry. Therefore, systematic testing is not optional — it is a regulatory and patient-safety imperative.

Furthermore, regulatory agencies worldwide — including the FDA and the European MDR framework — now require manufacturers to validate reprocessing instructions and demonstrate that chemical and physical integrity holds across the intended number of reuse cycles. Consequently, a robust testing program protects both patients and manufacturers from costly failures.

Key Takeaways

Reusable medical device testing confirms chemical, structural, and biological safety after repeated reprocessing.

Regulatory bodies require validated reprocessing instructions and multi-cycle performance data.

Chemical characterization, biocompatibility, and material integrity testing form the core testing triad.

ISO 10993-18 and FDA guidance documents set the framework for chemical evaluation.

Early-stage testing partnerships reduce costly late-cycle regulatory surprises.

Analytical methods such as FTIR, GC-MS, HPLC, and XRF each serve specific detection roles.

Reusable medical device testing: A systematic analytical and biological evaluation process that assesses whether a medical device retains material integrity, chemical safety, and functional performance after undergoing one or more reprocessing cycles — including cleaning, disinfection, and sterilization — in accordance with applicable regulatory standards such as ISO 10993 and FDA guidance.

Key fact: Inadequate reprocessing of reusable medical devices is one of the leading documented causes of healthcare-associated infection outbreaks investigated by regulatory agencies globally.

What Are Reusable Medical Devices and How Are They Regulated?

Reusable medical devices span a broad range of product categories. Surgical instruments, endoscopes, orthopedic implant trials, dental handpieces, and diagnostic probes all fall under this classification. Moreover, the regulatory obligations tied to reusability differ significantly from those governing single-use products.

Specifically, a device qualifies as reusable when its labeling and design intend multiple uses on multiple patients, with reprocessing steps between each use. Consequently, manufacturers must provide validated reprocessing instructions — not simply recommend a generic cleaning protocol.

How Regulatory Agencies Define Reusable Devices

The FDA classifies reusable devices under its Quality System Regulation and device-specific guidance documents. In addition, the European Medical Device Regulation (EU MDR 2017/745) places strict demands on manufacturers to demonstrate that devices withstand the number of reprocessing cycles stated in their instructions for use (IFU).

Therefore, the IFU becomes a critical document — it must reflect actual validated performance, not theoretical assumptions. Importantly, regulators scrutinize IFU claims during premarket submissions and post-market surveillance audits.

Device Classification and Risk Levels

Risk classification directly shapes the testing burden. Class I devices, such as basic stainless-steel retractors, typically face lower analytical demands. Meanwhile, Class II devices — for example, powered surgical tools — require more extensive validation. By contrast, Class III devices like reusable cardiac catheters demand the most rigorous chemical characterization and biocompatibility data packages.

Furthermore, the Spaulding classification — critical, semi-critical, and non-critical — determines the appropriate sterilization or disinfection level required between uses. Consequently, testing programs must align with both the FDA device class and the Spaulding category to satisfy regulators fully.

Additionally, post-market obligations apply throughout a device’s commercial life. Manufacturers must monitor field complaints, assess design changes, and repeat relevant testing whenever materials or reprocessing steps change. For related context on how material equivalency affects these decisions, see our article on device material equivalency and compliance.

Why Reusable Medical Device Testing Requires a Multi-Disciplinary Approach

No single test method captures all the risks associated with repeated device use. Consequently, effective reusable medical device testing draws on chemistry, materials science, microbiology, and toxicology simultaneously. Each discipline reveals a different failure mode that the others might miss.

For example, a device may pass mechanical integrity checks while leaching toxic degradation products that only GC-MS Analysis or HPLC Analysis would detect. Therefore, a tiered, multi-method strategy is essential from the earliest stages of device development.

Chemical Characterization as the Foundation

Chemical characterization identifies and quantifies substances that may migrate from device materials into patient contact environments. In particular, ISO 10993-18 requires manufacturers to compile a chemical characterization report that covers all materials of construction and their potential extractables and leachables. For a full overview of this regulatory framework, consult ISO 10993-18 Chemical Characterization.

Furthermore, the characterization must reflect realistic worst-case conditions — including the solvents, temperatures, and cycles used during reprocessing. Our Chemical & Elemental Characterization services apply this standard systematically, helping teams build defensible data packages early.

Biocompatibility Assessment After Reprocessing

Biocompatibility evaluation goes beyond simple cytotoxicity screens. Specifically, repeated reprocessing cycles can generate new chemical entities — oxidation products, polymer degradation fragments, or residual sterilant residues — that require fresh toxicological assessment. Our Biocompatibility & Toxicity Testing services address these evolving chemical profiles.

Additionally, the ISO 10993-1 biological evaluation plan must account for changes in the device’s surface chemistry over its intended use life. Therefore, testing at simulated end-of-life conditions, not just initial use, is a regulatory expectation. For a deeper discussion of how biocompatibility programs connect to broader risk strategy, review our post on risk-based biocompatibility testing.

Material Integrity and Surface Analysis

Repeated sterilization cycles — autoclave, EtO, gamma, or hydrogen peroxide plasma — stress device materials in different ways. Consequently, surface analytical techniques become critical for detecting micro-level degradation that visual inspection misses. SEM Analysis reveals surface cracking, pitting, and coating delamination at high resolution.

Moreover, XPS Analysis quantifies changes in surface elemental composition and oxidation states after sterilization exposure. By comparison, bulk material changes — such as crystallinity shifts in polymers — respond well to DSC Testing. Together, these methods paint a complete picture of material aging.

Quick note: Surface changes detectable only by SEM or XPS can precede visible corrosion or mechanical failure by many reprocessing cycles. Early-stage surface analysis can therefore prevent late-stage device recalls.

What Does a Reusable Medical Device Testing Program Include?

A complete reusable medical device testing program covers chemical, biological, physical, and functional performance domains. Moreover, it must simulate real-world conditions — not idealized laboratory conditions — to satisfy regulators and protect patients.

Specifically, the program should define: the number of reprocessing cycles to simulate, the worst-case reprocessing conditions, the patient contact duration and route, and the analytical endpoints at each evaluation stage. Overall, a well-structured plan aligns every test with a specific regulatory requirement or identified risk.

Extractables and Leachables Testing

Extractables studies identify compounds that could migrate under aggressive extraction conditions. Leachables studies then focus on what actually migrates under realistic clinical use conditions. Therefore, extractables data guides the analytical scope of leachables studies — it is a sequential, risk-driven process.

Importantly, reusable devices face a compounding challenge: leachable profiles can shift after each reprocessing cycle as surface layers erode or chemical bonds break. As a result, testing at multiple cycle intervals — for example, at 10, 50, and the maximum labeled reprocessing cycles — often reveals trends that single-point testing misses. Our Chemical Purity & Contaminant Screening capabilities support full extractables and leachables workflows.

Analytical Methods Used in Extractables and Leachables Testing

Several complementary analytical techniques address different chemical classes. The table below summarizes common methods and their primary application in reusable device testing.

Analytical Method	Primary Target	Typical Application
GC-MS	Volatile and semi-volatile organics	Residual sterilants, plasticizers, monomers
HPLC	Non-volatile organics and polymer additives	Antioxidants, colorants, UV stabilizers
XRF Analysis	Elemental screening	Surface metal contamination, coating integrity
FTIR Analysis	Polymer identification and surface chemistry	Material degradation, residue identification
NMR Spectroscopy	Structural organic characterization	Unknown compound identification
Raman Spectroscopy	Molecular fingerprinting	Coating verification, contamination mapping

Furthermore, elemental impurity analysis aligns with frameworks such as USP General Chapter <232> Elemental Impurities, which provides allowable daily exposure limits for heavy metals and other toxic elements that may leach from device components or cleaning agents.

Sterilization Residue and Cleaning Agent Validation

Reprocessing agents introduce their own chemical risks. Ethylene oxide sterilization, for instance, leaves behind EtO residues and reaction byproducts such as ethylene chlorohydrin. Similarly, enzymatic cleaning agents and high-level disinfectants may leave trace residues that interact with device surfaces unpredictably.

Therefore, testing must include sterilant residue analysis, cleaning agent carryover studies, and confirmation that rinsing protocols achieve acceptable residue limits. In addition, Wet Chemistry & Classical Analytical Methods play an important role in validating pH, ion concentrations, and residue thresholds that chromatographic techniques alone may not fully address.

For teams navigating FDA feedback on chemical data packages, our article on FDA chemical characterization review provides practical guidance on addressing common agency concerns.

Selecting the Right Extraction Solvent and Conditions

Solvent selection profoundly influences extractables study outcomes. Aqueous, polar organic, and non-polar solvents each target different chemical classes. Importantly, ISO 10993-18 and FDA guidance both recommend a polarity-bracketing approach — using multiple solvents to maximize compound coverage.

In addition, extraction temperature and duration must reflect worst-case clinical exposure. Consequently, a room-temperature aqueous rinse may drastically underestimate the true leachable burden compared to an exhaustive reflux extraction. Our Method Development & Validation team customizes extraction protocols to match each device’s unique contact scenarios.

For teams seeking broader analytical guidance on best practices in chemical analysis, ScienceDirect – Analytical Methods provides peer-reviewed research covering extraction methodologies relevant to medical device chemistry. Additionally, PubMed Central – Trace Metals Review offers extensive literature on trace element migration and its toxicological implications.

How Do Advanced Analytical Techniques Support Reusable Medical Device Testing?

Advanced elemental and spectroscopic methods deliver detection sensitivity that standard screening tools cannot match. Consequently, laboratories rely on techniques like ICP-MS, ICP-OES, and AAS when trace-level contamination poses patient risk. These instruments quantify metals and metalloids at parts-per-billion or even parts-per-trillion concentrations.

Furthermore, combining multiple advanced methods within a single testing program improves both coverage and confidence. Our Chemical & Analytical Testing services integrate these platforms into coordinated workflows tailored for reusable device programs.

ICP-MS and ICP-OES for Elemental Impurity Detection

Inductively coupled plasma mass spectrometry (ICP-MS) excels at detecting toxic heavy metals — arsenic, cadmium, lead, and mercury — at ultra-trace levels. Notably, ICP-MS aligns directly with the permissible daily exposure limits established by USP Elemental Impurities guidelines and ISO 10993-18 requirements.

By comparison, ICP-OES offers broader dynamic range and suits higher-concentration elemental work, such as confirming alloy composition after repeated sterilization cycles. Together, these two platforms cover a wide elemental mass range. As a result, laboratories often run both in parallel to maximize data completeness.

Atomic Absorption Spectroscopy in Device Testing

Atomic absorption spectroscopy (AAS) provides targeted, single-element quantification at high sensitivity. Specifically, graphite furnace AAS suits low-volume extracts where precious sample is limited — a common constraint in endoscope or catheter testing scenarios.

Moreover, flame AAS handles bulk metal analysis efficiently when sample volume is sufficient and throughput demands are high. Therefore, AAS remains a valuable complementary tool alongside ICP methods in comprehensive Chemical & Elemental Characterization programs. Peer-reviewed analytical methodology supporting these applications appears regularly in ScienceDirect journals.

Hyphenated Techniques for Unknown Compound Identification

Hyphenated platforms — LC-MS/MS, GC-MS/MS, and GC-QTOF — combine separation power with high-resolution mass detection. Consequently, these tools identify unknown degradation products and reaction byproducts that simple unit-resolution instruments miss.

In particular, reprocessing-induced degradation can generate novel compounds with no reference standard available. High-resolution accurate mass data then allows structure elucidation from first principles. Therefore, hyphenated platforms have become indispensable for comprehensive extractables profiling in complex reusable device programs. Our Method Development & Validation scientists design these workflows from the ground up.

Reusable Medical Device Testing Across Different Device Categories

Different device categories present unique reprocessing challenges. Consequently, testing strategies must adapt to each device’s materials, geometry, intended use, and regulatory classification. A one-size-fits-all approach consistently falls short under regulatory scrutiny.

Furthermore, patient populations — neonatal, immunocompromised, or elderly — influence acceptable risk thresholds. Therefore, a device intended for intensive care units may require more stringent leachable limits than one used in low-risk outpatient procedures.

Endoscopes and Minimally Invasive Devices

Flexible endoscopes present one of the most demanding reusable medical device testing challenges. Their complex internal channels, adhesive bonds, and mixed-material construction create multiple sites for biofilm retention and chemical degradation. Moreover, endoscope-associated infections have drawn repeated attention from the FDA and global health authorities.

Specifically, lumen surface chemistry must remain stable across hundreds of high-level disinfection cycles. As a result, surface characterization by XPS Analysis and SEM Analysis provides critical evidence of channel integrity. Additionally, disinfectant residue testing ensures glutaraldehyde or peracetic acid carryover remains within safe limits.

Surgical Instruments and Implant Trials

Stainless steel and titanium instruments dominate surgical trays. However, repeated autoclaving can induce surface oxidation, pitting corrosion, and passive layer breakdown on even high-grade alloys. Consequently, elemental leaching from corroded surfaces warrants regular monitoring throughout the product’s validated use life.

Orthopedic implant trial sets — used intraoperatively and reprocessed repeatedly — introduce additional complexity. Notably, these devices contact bone, joint fluid, and blood simultaneously, which raises the toxicological stakes considerably. Our Biocompatibility & Toxicity Testing team evaluates these scenarios systematically, including cytotoxicity, sensitization, and genotoxicity endpoints where applicable.

Diagnostic Probes and Monitoring Equipment

Ultrasound probes, temperature sensors, and physiological monitoring electrodes all contact patients repeatedly. Specifically, gel transducer covers, cable jacketing, and probe tip materials degrade with repeated disinfection. Furthermore, some high-level disinfectants attack the adhesives that seal probe housings, creating pathways for fluid ingress and internal contamination.

Therefore, testing programs for diagnostic devices must evaluate both external surface chemistry and seal integrity across simulated use cycles. In addition, material compatibility testing between device components and approved reprocessing agents forms an essential part of the IFU validation package. For insight into how FDA reviewers assess chemical data in these submissions, our article on FDA biocompatibility deficiencies highlights the most common gaps agencies identify.

Quality Assurance and Best Practices in Reusable Medical Device Testing Programs

A rigorous quality framework transforms individual test results into defensible regulatory evidence. Consequently, every element of the testing program — from sample preparation to data interpretation — must operate under documented, validated procedures. Quality assurance is not a final checkpoint; it is a continuous process embedded throughout the program.

Moreover, selecting an experienced testing partner early in device development prevents costly rework at the submission stage. Our Scientific & Technical Consulting team helps manufacturers design compliant testing strategies from the outset, long before regulatory submissions begin.

Documenting the Biological Evaluation Plan

The biological evaluation plan (BEP) anchors every ISO 10993-compliant testing program. Specifically, the BEP defines the rationale for each test selected or waived, links device materials to known chemical hazards, and sets the sequence of chemical and biological assessments. Regulators expect this document early in the premarket review process.

Furthermore, the BEP must evolve when materials change, reprocessing instructions update, or new clinical use conditions emerge. Therefore, treating the BEP as a living document — rather than a static submission artifact — reflects best practice and reduces post-market compliance risk. For broader context on biocompatibility program design, see our post on risk-based biocompatibility testing.

Simulated Use and Accelerated Aging Protocols

Simulated use studies subject devices to the full number of labeled reprocessing cycles under controlled laboratory conditions. Importantly, these studies must replicate the worst-case scenario — maximum soak times, highest approved temperatures, and most aggressive approved cleaning agents — to satisfy regulatory expectations.

Accelerated aging protocols compress multi-year use lifespans into manageable study durations. By contrast, real-time aging studies run concurrently to confirm accelerated model predictions. Together, both approaches provide the temporal data regulators need to approve the stated reuse claim on device labeling.

Comparison of Testing Program Approaches

The table below compares phased versus comprehensive reusable medical device testing program structures, helping teams choose the right approach for their regulatory pathway and resource constraints.

Program Element	Phased Approach	Comprehensive Approach
Chemical characterization timing	Conducted at key milestones	Continuous throughout development
Cycle interval testing	Start, midpoint, and end	Multiple intermediate intervals
Analytical method breadth	Targeted screening methods	Full hyphenated and elemental suite
Biocompatibility depth	Risk-justified endpoint selection	All ISO 10993-1 endpoints evaluated
Regulatory risk	Moderate — gaps possible	Low — broad data coverage
Resource investment	Lower upfront cost	Higher upfront, lower rework cost

Data Integrity and Laboratory Accreditation

Regulatory agencies expect data generated under ISO 17025-accredited laboratory conditions. Specifically, accreditation confirms that methods are validated, instruments are calibrated, and results are traceable to recognized reference standards. Submitting data from non-accredited sources frequently triggers FDA or notified body requests for additional information.

In addition, electronic data integrity — audit trails, access controls, and raw data retention — matters as much as the analytical results themselves. Therefore, partnering with a laboratory that maintains robust data governance systems directly reduces regulatory review timelines. Our Chemical & Analytical Testing services operate within quality management systems designed to meet these expectations. Guidance on chemical evaluation frameworks also appears in the current version of ISO 10993-18, which laboratories and manufacturers should consult directly when designing study protocols.

Quick note: Regulatory submissions that include pre-validated analytical methods and ISO 17025 accreditation certificates consistently move through review faster than those that do not. Data quality documentation is not optional paperwork — it is a competitive advantage in the approval process.

Frequently Asked Questions About Reusable Medical Device Testing

What standards govern reusable medical device testing?

Several interconnected standards apply. ISO 10993-1 sets the overall biological evaluation framework, while ISO 10993-18 specifically governs chemical characterization of device materials. Furthermore, FDA guidance documents on reprocessing of reusable devices, AAMI TIR17, and EU MDR 2017/745 annex requirements all shape program design. Consequently, manufacturers must consult multiple frameworks in parallel rather than relying on a single standard.

How many reprocessing cycles must a device be tested through?

Regulators require testing through the maximum number of cycles stated in the device’s instructions for use. Specifically, the IFU cycle claim must be validated — not estimated. Therefore, if a manufacturer labels a device for 100 reuse cycles, the testing program must simulate all 100 cycles under worst-case conditions. Importantly, claiming fewer cycles to reduce testing burden can limit commercial appeal and market competitiveness.

What is the difference between extractables and leachables in device testing?

Extractables are compounds that migrate under aggressive, controlled laboratory conditions — high temperatures, strong solvents, and extended contact times. By contrast, leachables are compounds that migrate under realistic clinical use conditions. Extractables studies define the analytical scope. Leachables studies then confirm what actually reaches the patient. Therefore, both studies are necessary, and extractables data directly informs leachables study design.

Can biocompatibility data from the original device be used for a modified reusable design?

Existing biocompatibility data may support a modified device only when material changes are minor and well-characterized. However, any change to materials, coatings, adhesives, or reprocessing instructions may introduce new chemical entities that invalidate prior biological evaluation conclusions. As a result, a gap analysis under ISO 10993-1 — comparing old and new material chemistries — is always required before relying on historical data. Our article on device material equivalency explores this topic in detail.

How long does a reusable medical device testing program typically take?

Program duration depends on the device’s complexity, the number of validated reuse cycles, and the regulatory pathway. Specifically, simulated use studies alone can require several weeks to months when running the full cycle count. In addition, biocompatibility endpoint testing, chemical characterization, and data reporting add further time. Overall, teams should plan for six to twelve months for a comprehensive program — and longer if design changes require repeat testing. Early engagement with a testing partner significantly reduces timeline risk.

What role does toxicological risk assessment play in reusable device testing?

Toxicological risk assessment (TRA) converts chemical characterization data into patient risk conclusions. Specifically, a qualified toxicologist evaluates each identified chemical against established health-based exposure limits — such as tolerable daily intake values and USP Elemental Impurities thresholds. Furthermore, the TRA determines whether identified leachables require additional biocompatibility testing or whether existing literature data suffices. Consequently, TRA is not a final step — it actively guides the analytical testing strategy from the earliest program stages.

Conclusion

Reusable medical device testing sits at the intersection of patient safety, regulatory compliance, and product durability. Consequently, manufacturers who invest in rigorous, multi-disciplinary testing programs from early development consistently achieve smoother regulatory submissions and stronger post-market standing. A fragmented or reactive approach, by contrast, leads to costly data gaps, submission delays, and potential field failures.

Furthermore, the analytical landscape continues to evolve. New regulatory guidance, improved detection technologies, and expanding toxicological databases all raise the bar for what constitutes an adequate chemical characterization and biocompatibility data package. Therefore, staying current with regulatory science is as important as selecting the right test methods.

Overall, the most successful reusable device programs share three characteristics: they start early, they integrate chemistry and biology from the outset, and they partner with laboratories equipped to handle the full analytical scope. Our team at Materials Metric combines accredited analytical capabilities, regulatory expertise, and deep experience across device categories to support every stage of your program.

If your team is planning a reusable medical device testing program — or needs to address gaps in an existing data package — contact Materials Metric today to discuss your specific device, regulatory pathway, and timeline requirements. Our scientists are ready to help you build a defensible, compliant, and efficient testing strategy from the ground up.